Novartis to acquire breast cancer drug SNV4818 for up to $3B
Pan-mutant selective PI3Kα inhibitor targets 40% of HR+/HER2- breast cancer patients with worse prognosis
Novartis agreed to acquire SNV4818, an experimental breast cancer drug, from Synnovation Therapeutics for up to $3 billion, strengthening its oncology pipeline in hormone receptor positive disease. The deal includes an upfront payment of $2 billion and up to $1 billion in milestone payments based on development, regulatory, and commercial achievements, according to the company's announcement.
SNV4818 is a pan-mutant selective PI3Kα inhibitor designed to target cancer cells with PIK3CA mutations while sparing healthy cells. The selective approach aims to reduce side effects and improve tolerability compared to existing PI3Kα inhibitors, which block both mutant and wild-type enzymes. This selectivity should enable more consistent dosing and easier combination with hormonal therapy and other treatments earlier in the disease course, Novartis stated in its press release.
The drug is currently in Phase 1/2 clinical studies for HR+/HER2- breast cancer and other advanced solid tumors. Approximately 40% of patients with HR+/HER2- breast cancer have PIK3CA mutations, which are associated with worse disease outcomes, representing a significant unmet medical need. Preclinical studies have demonstrated strong activity against common PIK3CA mutations and clear selectivity over the normal enzyme, according to Novartis.
The acquisition aligns with Novartis's oncology strategy in breast cancer, where it already markets Kisqali (ribociclib), a CDK4/6 inhibitor. SNV4818 is designed to complement CDK inhibitors and endocrine therapies as part of combination regimens. Novartis expects the transaction to close in the first half of 2026, according to the Wall Street Journal.
Novartis shares were trading at $148.19, down 1.08% in midday Thursday trading, giving the Swiss drugmaker a market capitalization of approximately $290 billion. The stock has traded within a 52-week range of $94.83 to $165.43. Analysts have an average price target of $146 on the stock, with 5 analysts rating it a hold and 3 rating it a buy or strong buy, according to market data.
The $3 billion potential deal value represents approximately 1% of Novartis's market capitalization, suggesting the company views SNV4818 as a meaningful but not transformational addition to its portfolio. The upfront payment of $2 billion indicates confidence in the drug's clinical potential despite its early-stage development. Novartis reported revenue of $56.7 billion over the trailing twelve months with a profit margin of 24.7%, according to financial data.
The breast cancer treatment market has grown increasingly competitive, particularly in the HR+/HER2- space where CDK4/6 inhibitors from Pfizer, Novartis, and Eli Lilly compete. PI3K inhibitors represent an additional mechanism of action for patients who develop resistance to standard therapies. Existing PI3Kα inhibitors have faced challenges due to toxicity and side effects, making the selective profile of SNV4818 potentially advantageous if clinical trials confirm its safety benefits.
Novartis's oncology division has been a growth driver for the company, and the acquisition continues its strategy of bolstering its pipeline through selective deals rather than large transformative acquisitions. The company has focused on areas with high unmet medical need and strong scientific rationale, fitting SNV4818's profile in targeting a mutation that affects a significant portion of breast cancer patients and is linked to poorer outcomes.
The deal comes as Novartis continues to optimize its portfolio following its separation from Sandoz, its generics and biosimilars business, in 2023. The company has emphasized oncology, immunology, and neuroscience as core focus areas. The breast cancer market represents one of the largest oncology segments globally, with HR+/HER2- disease accounting for approximately 70% of all breast cancer cases.